Alto Neuroscience, Inc.
$27.33
▼
-7.39%
2026-04-21 05:19:00
www.altoneuroscience.com
NYQ: ANRO
Explore Alto Neuroscience, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$885.53 M
Current Price
$27.33
52W High / Low
$28.11 / $2.09
Stock P/E
—
Book Value
$4.74
Dividend Yield
—
ROCE
-38.28%
ROE
-41.8%
Face Value
—
EPS
$-2.19
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
68
Beta
2.06
Debt / Equity
15.85
Current Ratio
15.69
Quick Ratio
15.69
Forward P/E
-10.01
Price / Sales
—
Enterprise Value
$575.19 M
EV / EBITDA
-8.75
EV / Revenue
—
Rating
Strong Buy
Target Price
$35.24
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
| 2. | Madrigal Pharmaceuticals, Inc. | $535 | — | $12.26 B | — | -31.61% | -42.49% | $615 / $265 | $26.39 |
| 3. | Vor Biopharma Inc. | $15.71 | — | $810.38 M | — | -84.67% | 2057.65% | $65.8 / $2.62 | $-8.1 |
| 4. | Estrella Immunopharma, Inc. | $1.81 | — | $80.21 M | — | 126.01% | 428.83% | $3.15 / $0.78 | $-0.27 |
| 5. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 6. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 7. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -17.05 M | -14.95 M | -18.68 M | -15.68 M | -17 M | — |
| Net Profit | -16.18 M | -14.18 M | -17.71 M | -15.17 M | -15.2 M | — |
| EPS in Rs | -0.51 | -0.44 | -0.55 | -0.47 | -0.48 | -0.62 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -66.36 M | -68.61 M | -37.81 M | -27.45 M |
| Net Profit | -63.24 M | -61.43 M | -36.3 M | -27.71 M |
| EPS in Rs | -1.98 | -1.92 | -1.14 | -0.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 184.69 M | 177.54 M | 86.63 M | 50.85 M |
| Total Liabilities | 33.55 M | 26.08 M | 158.3 M | 89.26 M |
| Equity | 151.14 M | 151.46 M | -71.67 M | -38.41 M |
| Current Assets | 177.72 M | 169.34 M | 85.39 M | 49.22 M |
| Current Liabilities | 11.32 M | 10.01 M | 5.61 M | 5.56 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.77 M | -47.42 M | -33.45 M | -20.39 M |
| Investing CF | -0.02 M | -2.08 M | -0.47 M | -0.73 M |
| Financing CF | 60.08 M | 135.69 M | 68.13 M | 43.79 M |
| Free CF | -51.79 M | -49.5 M | -33.92 M | -21.13 M |
| Capex | -0.02 M | -2.08 M | -0.47 M | -0.73 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -69.21% | -31.02% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.